HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could less radiation be enough? new study aims to reduce treatment side effects for HPV-Related throat cancer
Disease control Recruiting nowThis study is for people with HPV-positive throat cancer. It tests whether the dose of radiation can be safely lowered if the tumor shrinks quickly during early treatment. The goal is to maintain cancer control while reducing side effects. About 120 participants will be enrolled.
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated May 17, 2026 01:00 UTC
-
Supercharged immune cells take on HPV cancers
Disease control Recruiting nowThis study tests a new immunotherapy for people with advanced HPV-related cancers (cervical, throat, anal, and others). Participants receive specially engineered immune cells designed to attack HPV-infected tumor cells, along with chemotherapy and a drug to boost cell activity. T…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New combo therapy aims to harness immune system against HPV-driven throat cancer
Disease control Recruiting nowThis study tests a new drug, CUE-101, alone or with pembrolizumab, in 30 people with newly diagnosed, advanced HPV-16 head and neck cancer that cannot be surgically removed. The goal is to see if these treatments can boost the body's immune cells to fight the tumor before standar…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Less radiation, same hope: new study aims to ease treatment for HPV throat cancer
Disease control Recruiting nowThis study is testing whether a lower dose of radiation can work just as well for people with HPV-positive throat cancer, while causing fewer side effects. Researchers will track 111 participants over two years to see if the cancer stays away. The goal is to make treatment easier…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Immune cells take aim at HPV tumors before standard therapy
Disease control Recruiting nowThis study tests whether giving a single dose of specially engineered immune cells (E7 TCR-T cells) before standard treatment (chemoradiation or surgery) can shrink or eliminate tumors in people with advanced HPV-related cancers. About 15 participants will have their own T cells …
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Blood test may spare throat cancer patients from unnecessary radiation
Disease control Recruiting nowThis study looks at whether a simple blood test can tell which throat cancer patients can safely skip radiation after surgery. About 61 people with HPV-related throat cancer will have their blood tested before and after surgery. If the test is negative after surgery and they are …
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug combo aims to shrink Hard-to-Treat head and neck tumors
Disease control Recruiting nowThis study tests whether combining two drugs, sacituzumab govitecan and cetuximab, can shrink tumors in people with advanced head and neck cancer that has returned or spread after initial treatment. About 40 adults whose cancer worsened after first-line therapy will receive the c…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New vaccine aims to train immune system against HPV cancers
Disease control Recruiting nowThis early-stage trial tests a new vaccine (Lenti-HPV-07) designed to help the immune system fight HPV-related throat and cervical cancers. About 72 adults with either advanced or newly diagnosed cancer will receive the vaccine. Researchers will monitor safety and whether the vac…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Theravectys S.A. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Blood test may spare some throat cancer patients from unnecessary radiation
Disease control Recruiting nowThis study is for people with HPV-related throat cancer who have had or will have surgery. Researchers will use a blood test that looks for cancer DNA (HPV ctDNA) to decide if radiation therapy is needed. In one group, patients with no detectable cancer DNA after surgery will ski…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 24, 2026 16:17 UTC